Free Trial

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Has Consensus Price Target of $6.14

Foghorn Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts have a consensus “Hold” rating on Foghorn Therapeutics, with six holds, four buys and one sell among 11 brokerages. Their average 1-year price target is $6.14.
  • Recent analyst changes were mixed but included notable downgrades and target cuts: Wedbush lowered its target from $10 to $2, while Guggenheim cut its target from $12 to $5 but maintained a Buy rating.
  • Foghorn reported quarterly EPS of $0.80, above the consensus estimate of a $0.24 loss, and revenue of $83.54 million versus estimates of $7.10 million. Shares opened at $2.07 and have ranged from $1.79 to $7.61 over the past year.
  • Interested in Foghorn Therapeutics? Here are five stocks we like better.

Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX - Get Free Report) have been given a consensus recommendation of "Hold" by the eleven brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $6.14.

A number of equities analysts have weighed in on FHTX shares. Evercore lowered Foghorn Therapeutics from an "outperform" rating to an "in-line" rating and set a $3.00 target price on the stock. in a research note on Tuesday, October 13th. Wedbush downgraded Foghorn Therapeutics from an "outperform" rating to a "neutral" rating and dropped their price target for the company from $10.00 to $2.00 in a research report on Friday, October 2nd. Guggenheim cut their price objective on Foghorn Therapeutics from $12.00 to $5.00 and set a "buy" rating for the company in a report on Friday, October 2nd. TD Cowen cut shares of Foghorn Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, October 1st. Finally, Stifel Nicolaus set a $5.00 price objective on shares of Foghorn Therapeutics in a research report on Thursday, October 1st.

View Our Latest Report on Foghorn Therapeutics

Foghorn Therapeutics Price Performance

Shares of NASDAQ:FHTX opened at $2.07 on Monday. The company has a 50-day moving average price of $2.79 and a two-hundred day moving average price of $4.52. The firm has a market capitalization of $124.12 million, a PE ratio of 29.58 and a beta of 3.22. Foghorn Therapeutics has a twelve month low of $1.79 and a twelve month high of $7.61.

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last posted its earnings results on Monday, November 9th. The company reported $0.80 earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $1.04. Foghorn Therapeutics had a negative return on equity of 13.46% and a net margin of 8.40%. The business had revenue of $83.54 million during the quarter, compared to analyst estimates of $7.10 million. Analysts anticipate that Foghorn Therapeutics will post -0.07 earnings per share for the current fiscal year.

Trending Headlines about Foghorn Therapeutics

Here are a few of the latest headlines about FHTX:

  • Positive Sentiment: Guggenheim maintained its Buy rating on Foghorn, reinforcing a positive analyst view. Guggenheim sticks to its Buy rating
  • Negative Sentiment: Pomerantz LLP said it is investigating potential claims on behalf of Foghorn investors. The notice does not establish wrongdoing, but the investigation may add legal uncertainty. Pomerantz investor alert
  • Negative Sentiment: HC Wainwright cut its Q4 2026 EPS forecast and substantially lowered estimates for FY2027–FY2030, now projecting annual losses in those years. The revisions point to a weaker longer-term earnings outlook despite the firm’s Buy rating. HC Wainwright analyst estimates

Hedge Funds Weigh In On Foghorn Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of FHTX. Empowered Funds LLC bought a new position in shares of Foghorn Therapeutics in the 3rd quarter worth $252,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Foghorn Therapeutics during the 3rd quarter valued at $48,000. Squarepoint Ops LLC lifted its holdings in shares of Foghorn Therapeutics by 25.6% during the 2nd quarter. Squarepoint Ops LLC now owns 130,346 shares of the company's stock worth $636,000 after acquiring an additional 26,603 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Foghorn Therapeutics during the 2nd quarter worth $127,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Foghorn Therapeutics during the 2nd quarter worth $122,000. Hedge funds and other institutional investors own 61.55% of the company's stock.

Foghorn Therapeutics Company Profile

(Get Free Report)

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for cancer. Its research centers on chromatin regulatory systems, which help control how genes are expressed and can contribute to disease when disrupted. The company's Gene Traffic Control platform is designed to identify drug targets within these systems. Foghorn has developed investigational programs targeting chromatin regulators, including components of the BAF complex; its candidates remain in development and are not approved medicines.

Featured Stories

Analyst Recommendations for Foghorn Therapeutics (NASDAQ:FHTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Foghorn Therapeutics Right Now?

Before you consider Foghorn Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Foghorn Therapeutics wasn't on the list.

While Foghorn Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines